The Ber-ACT8 monoclonal antibody specifically binds to the human mucosal lymphocyte antigen 1 (HML-1). This is a 175 kDa type I transmembrane glycoprotein, also known as integrin αE (ITGAE, Integrin alpha-E) and CD103. It is found on >90% of intestinal intraepithelial lymphocytes (iIEL) associated with integrin β7. CD103 is also expressed on lamina propria T lymphocytes in the intestine and on phytohemagglutinin-stimulated peripheral blood lymphocytes. It is rarely expressed on resting peripheral blood lymphocytes. It has been suggested that CD103 may have an accessory function for activation of iIEL. CD103 has been reported as a useful tool in hairy cell leukemia research.
The antibody was conjugated to BD Horizon™ BUV661 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye is a tandem fluorochrome of BD Horizon BUV395 with an Ex Max of 348-nm and an acceptor dye with an Em Max at 661-nm. BD Horizon Brilliant BUV661 can be excited by the ultraviolet laser (355 nm) and detected with a 670/25 filter and a 630 nm LP. Due to cross laser excitation of this dye, there may be significant spillover into channels detecting APC-like emissions (eg, 670/25-nm filter).
Due to spectral differences between labeled cells and beads, using BD™ CompBeads can result in incorrect spillover values when used with BD Horizon BUV661 reagents. Therefore, the use of BD CompBeads or BD CompBeads Plus to determine spillover values for these reagents is not recommended. Different BUV661 reagents (eg, CD4 vs. CD45) can have slightly different fluorescence spillover therefore, it may also be necessary to use clone-specific compensation controls when using these reagents.